Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immunocore signs on Genentech as first major partner to develop ImmTACs; expanded

Executive Summary

Roche’s Genentech Inc. has licensed rights to discover, develop, and market UK immunotherapeutics firm Immunocore Ltd.’s biologic candidates called ImmTACs (Immune mobilizing mTCR Against Cancer) directed at several novel oncology targets.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register